Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 7/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 5/20 | 0.36 |
| ▸ | CLK3 | P49761 | 5/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493936 | 0.87 | MEN1 (0.43) | PIM1BTKCLK2CLK3DYRK1A | |
| SCHEMBL6372381 | 0.83 | NTRK1 (0.41) | PIM1NTRK1BTKCLK2CLK3 | |
| SCHEMBL6367003 | 0.81 | HCRTR1 (0.43) | PIM1NTRK1DYRK1APARP1 | |
| SCHEMBL6372415 | 0.81 | PDE5A (0.52) | NTRK1PNP | |
| SCHEMBL3494974 | 0.80 | AR (0.41) | PIM1NTRK1BTKCLK2CLK3 | |
| SCHEMBL6367719 | 0.79 | CACNA1H (0.39) | PIM1NTRK1CLK2CLK3DYRK1A | |
| SCHEMBL6371898 | 0.78 | IDO1 (0.40) | PIM1BTKCLK2CLK3DYRK1A | |
| SCHEMBL3492777 | 0.78 | PDE9A (0.54) | BTKCLK2CLK3DYRK1AIDO1 | |
| SCHEMBL6366070 | 0.76 | PDE9A (0.44) | CLK2CLK3DYRK1AIDO1LRRK2 | |
| SCHEMBL6371987 | 0.76 | PDE9A (0.40) | PIM1BTKIDO1LRRK2PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PIM1 1560/4885NTRK1 4612/4885BTK 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.